Eli Lilly 2011 Annual Report Download - page 8
Download and view the complete annual report
Please find page 8 of the 2011 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.-
1 -
2 -
3 -
4 -
5 -
6 -
7 -
8 -
9 -
10 -
11 -
12 -
13 -
14 -
15 -
16 -
17 -
18 -
19 -
20
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40
-
41
-
42
-
43
-
44
-
45
-
46
-
47
-
48
-
49
-
50
-
51
-
52
-
53
-
54
-
55
-
56
-
57
-
58
-
59
-
60
-
61
-
62
-
63
-
64
-
65
-
66
-
67
-
68
-
69
-
70
-
71
-
72
-
73
-
74
-
75
-
76
-
77
-
78
-
79
-
80
-
81
-
82
-
83
-
84
-
85
-
86
-
87
-
88
-
89
-
90
-
91
-
92
-
93
-
94
-
95
-
96
-
97
-
98
-
99
-
100
-
101
-
102
-
103
-
104
-
105
-
106
-
107
-
108
-
109
-
110
-
111
-
112
-
113
-
114
-
115
-
116
-
117
-
118
-
119
-
120
-
121
-
122
-
123
-
124
-
125
-
126
-
127
-
128
-
129
-
130
-
131
-
132
-
133
-
134
-
135
-
136
-
137
-
138
-
139
-
140
-
141
-
142
-
143
-
144
-
145
-
146
-
147
-
148
-
149
-
150
-
151
-
152
-
153
-
154
-
155
-
156
-
157
-
158
-
159
-
160
-
161
-
162
-
163
-
164
 |
 |
6
Transformation is everywhere at Lilly. We’re fi nding
innovative ways to conduct research, to connect with
customers, and to operate more effi ciently in every
area of our business. Each of the individuals pictured
here represents the combined effort of a team of
Lilly employees, and these stories are but examples
of countless initiatives by their colleagues across
the company. All these efforts support a common
mission—to make medicines that help people live
longer, healthier, more active lives.
DISCOVERY:
Accessing molecules through open innovation
Marta Piñeiro-Núñez, Ph.D., director, open innovation drug
discovery, builds relationships with academic scientists.
We’re opening the door for accessing promising mol-
ecules around the world with an innovative approach
to collaborating with scientists in academia and small
biotech companies.
In 2009, we launched the Lilly Phenotypic Drug
Discovery Initiative, known as “PD2,” and we expanded
the program in 2011 under the banner of Open Innova-
tion Drug Discovery.
Through this program, Lilly carries out screening
tests—free of charge—on compounds submitted by
outside researchers. In return, we retain fi rst rights to
negotiate an agreement with them. If no such agreement
results, external researchers receive no-strings-attached
ownership of the data report from Lilly to use as they see
fi t in publications, grant proposals, or further research.
By the end of 2011, more than 200 universities,
research institutes, and small biotechs representing 25
countries were affi liated with the program, and we re-
ceived some 84,000 chemical structures uploaded into our
database for evaluation. Of these, we’ve evaluated more
than 14,000 physical samples, the vast majority of which
are structurally distinct from those in our compound col-
lection. We’ve entered fi ve collaborations, all ongoing.
We believe that open innovation signifi cantly
complements our internal efforts, leveraging our resourc-
es to discover potential new medicines.
Transforming Challenges into
Advances: Lilly People in Action